Abivax S.A. (ABVX) stock
Close on Nov 11, 2026Market cap $7.18BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- €6.44B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -2.50%
Fundamentals
- EPS, diluted
- -4.83 EUR
- Free cash flow
- -€197.27M
- Diluted shares
- 80M
Trading
- Previous close
- $90.00
- Open
- $91.00
- Day's range
- $90.70 – $92.95
- Volume
- 739,089
- Average volume (20 days)
- 894,626
- Beta (5 years)
- 2.26
- RSI (14 days)
- 51.7
- Volatility (1 year)
- 86.4%
- Relative volume
- 0.70×
- WACC
- 16.2%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABVX | S&P 500 | Difference | ABVX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.7% | -2.4% | +6.1 pts | ||
| 3 months | -27.9% | -1.2% | −26.7 pts | ||
| Year to date | -32.2% | +12.3% | −44.5 pts | ||
| 1 year | -16.2% | +12.4% | −28.6 pts | ||
| 3 years | +814.4% | +78.8% | +735.6 pts | +109.1% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, EUR
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Abivax filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Abivax
Pharmaceutical Preparations
The entity (operating under the ticker identifier ABVX) operates in biotechnology and therapeutic asset development, conducting research, intellectual property licensing, and contract clinical programs. Its development pipeline centers around project assets such as ABX464 and ABX196, managed in part via licensing contracts and collaborations with research and academic institutions. The filing mentions no retail customer base or direct commercial consumers, indicating an operational emphasis on clinical development, research licensing, and project advancement.
Company profile, executives and historyAbivax stock: common questions
What is Abivax's stock price?
ABVX closed at $91.44 on Nov 11, 2026, up 1.60% on the day.
What is Abivax's market cap?
Abivax was worth $7.18B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ABVX's P/E ratio?
Abivax lost money over fiscal 2025 (diluted EPS -4.83 EUR), so it has no meaningful P/E ratio.
Does Abivax pay a dividend?
No. Abivax has not paid a cash dividend over the last twelve months.
How has ABVX stock performed over the past year?
Including dividends, ABVX returned -16.2% over the past year, against +12.4% for the S&P 500.
Who are Abivax's competitors?
Companies most similar to Abivax by business, industry and size include OCEA, CDT, LGND, ASMB, HELP.
See a number that looks wrong?